Bilthoven Biologicals

What Bilthoven Biologicals does

Bilthoven Biologicals (BBio) is a Dutch vaccine manufacturer and biopharmaceutical CDMO headquartered at the historic Bilthoven campus (Antonie van Leeuwenhoeklaan 9, 3721 MA), tracing its scientific lineage to a 1909 state laboratory that later became part of the Dutch National Institute for Public Health and the Environment (RIVM). The company was formed in its current private-company guise in 2012 when the Cyrus Poonawalla Group acquired the vaccine-producing division of the Nederlands Vaccin Instituut (NVI). It is a wholly-owned subsidiary of the Cyrus Poonawalla Group alongside Serum Institute of India (the world's largest vaccine manufacturer by volume), Serum Life Sciences Europe, and Serum Life Sciences UK.

BBio's product portfolio spans Inactivated Poliovirus Vaccine (IPV), Oral Poliovirus Vaccine (OPV), a DT-IPV combination, Tetanus vaccine, BCG (for tuberculosis), the SIILTIBCY® immunodiagnostic for TB, and a bladder cancer immunotherapy. Manufacturing is anchored by BSL 2/3 certified facilities running viral vector and Vero cell line platforms with commercial-scale capacity up to 2,000L, complemented by fill-finish capabilities and supply chain agreements with European component suppliers. The company holds ISO 9001, ISO 14001, GDPR, GMP, GDP, MIA, and BSL 2/3 certifications, and serves as Marketing Authorization Holder in Europe for IPV, Tetanus, and DT-IPV. A pandemic preparedness facility has been designated by the European Commission as one of six EU sites for viral vector vaccines, with a contractual obligation to be operational within three months of an outbreak and 300 million dose annual capacity at full operation.

BBio monetizes through three primary streams: direct vaccine product sales to governments and international health organizations (UNICEF, PAHO, Gavi, WHO, Bill & Melinda Gates Foundation-supported programs) under negotiated institutional contracts; CDMO services covering process development, clinical scale, and commercial scale manufacturing for pharmaceutical and biotech clients; and Investigational Medicinal Product (IMP) services including importation, QC testing, IMPD review, batch certification, and shipment to clinical trial sites across Europe. It serves 90+ countries with active partnerships and reports 500 million lives impacted through vaccine distribution globally, while also acting as the Cyrus Poonawalla Group's regulated European gateway for Serum Institute of India products, with first SII product introductions to the EU occurring in 2025.

Name

Bilthoven Biologicals

Legal name

Bilthoven Biologicals BV

Website

https://bbio.nl

Company type

Private

Founded year

1909

Operating status

Operating

Headcount range

101–250 employees

Short description

Bilthoven Biologicals is a Dutch B2B vaccine manufacturer producing IPV, OPV, DT-IPV, Tetanus, and BCG vaccines, plus CDMO and IMP services for governments, international health organizations, and pharmaceutical partners; it is a subsidiary of the Cyrus Poonawalla Group.

Ownership category

akta.pro rank

Product category

Vaccine Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Vaccine Clinical Development & Regulatory Affairs (HLAIAEAM), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

Keywords

• Vaccine manufacturing
• Biopharmaceutical products
• Contract manufacturing services
• Pandemic preparedness vaccines
• Polio vaccines

Headquarters

HQ city

Bilthoven

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Vaccine Product Sales: Sale of vaccines including IPV, OPV, DT-IPV, Tetanus, BCG, and other biological products to governments, NGOs, and healthcare providers for national immunization programs.
2. CDMO/Contract Manufacturing Services: GMP manufacturing services for clinical and commercial scale production, including process development, clinical scale manufacturing, and commercial scale manufacturing up to 2000L under BSL 2/3 conditions.
3. IMP Services: Services for Investigational Medicinal Products including physical importation, QC testing, IMPD review, batch certification and release for clinical trials, and shipment to clinical sites.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Bilthoven Biologicals manufactures and supplies vaccines and biological products (IPV, OPV, DT-IPV, Tetanus, BCG, and SIILTIBCY tuberculosis immunodiagnostic) for national immunization programs, and provides Contract Development and Manufacturing Organization (CDMO) services using viral vector and Vero cell line platforms in BSL 2/3 certified facilities. The company also offers Investigational Medicinal Product (IMP) services including QC testing, batch certification and release, and clinical trial material distribution across Europe.

Product overview

Bilthoven Biologicals operates as an end-to-end vaccine manufacturer with a comprehensive portfolio of biological products and contract manufacturing services. The company's core product portfolio includes six vaccine products: Tetanus Vaccine, SIILTIBCY® (rdESAT-6 and rCFP-10) for TB detection, Oral Poliomyelitis Vaccine (OPV), Inactivated Poliomyelitis Vaccine (IPV), Combination DT-IPV vaccine, and BCG vaccine. Additionally, the company offers pioneering bladder cancer immunotherapy. Complementing its product portfolio, Bilthoven Biologicals provides CDMO (Contract Development and Manufacturing Organization) services including process development, clinical and commercial scale manufacturing up to 2000L under BSL 2/3 conditions, as well as Investigational Medicinal Product (IMP) services for clinical trials including QC testing, batch certification, and European distribution.

Differentiator

Problem solved

Functional benefit

Brands

• SIILTIBCY: Immunodiagnostic product (rdESAT-6 and rCFP-10) for tuberculosis detection

Products and services

• Tetanus Vaccine

Quantifiable outcome

• 300 million IPV doses delivered since 1909
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered flagship and core.

• Serum Institute of IndiaflagshipTechnology or Integration · 1 January 2012Parent company acquisition in 2012 by the Cyrus Poonawalla Group. Combines Dutch scientific rigor with global reach and manufacturing scale. Serum Institute is the world's largest vaccine manufacturer.
• UNICEFcoreStrategic or Co-development PartnerBilthoven Biologicals collaborates with UNICEF to provide poliomyelitis vaccines to underserved regions, supporting vulnerable populations and strengthening health systems across Africa, Middle East, Asia, and Europe.
• PAHOcoreStrategic or Co-development PartnerPartnership with Pan American Health Organization for poliomyelitis vaccine supply and health system strengthening across the Americas region.
• Bill & Melinda Gates FoundationcoreStrategic or Co-development PartnerGlobal health partnership for improving vaccine accessibility worldwide. The Gates Foundation logo appears on the company website as a global partner.
• GavicoreStrategic or Co-development PartnerPartnership with Gavi, the Vaccine Alliance, for supporting immunization programs in developing countries and improving vaccine access.
• WHOcoreStrategic or Co-development PartnerWorld Health Organization partnership for global health initiatives and vaccine accessibility programs.
• VACSERA (Egypt)coreStrategic or Co-development PartnerPartnership with VACSERA in Egypt for the manufacturing of Inactivated Polio Vaccines, increasing accessibility to vaccines in Africa through technology transfer and local production.
• European CommissionflagshipStrategic or Co-development PartnerEuropean Commission designated Bilthoven Biologicals as one of six production sites for pandemic preparedness across Europe, specializing in viral vector vaccines. The facility must be operational within three months of a pandemic outbreak to supply the EU.
• Serum Life Sciences EuropecoreTechnology or IntegrationSister company within the Cyrus Poonawalla Group providing clinical trial management and translational project management services.
• Serum Life Sciences UKcoreTechnology or IntegrationSister company within the Cyrus Poonawalla Group serving as UK Corporate Office.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Bharat Biotech: India-based vaccine and biologics manufacturer with WHO-prequalified polio and combination vaccines supplied to Gavi/UNICEF; a peer Asian manufacturer competing for similar institutional buyers and capacity.
• Sanofi Pasteur: Sanofi's vaccines division is a global vaccine manufacturer with established polio, diphtheria-tetanus and combination vaccine franchises serving UNICEF and national immunization programs, competing with BBio for tenders and CDMO partnerships.
• VACSERA (Egypt): Egyptian state-affiliated vaccine and biological products manufacturer and existing BBio tech-transfer partner for IPV manufacturing; both are regional manufacturers targeting African and Middle East immunization markets.
• Sinovac Biotech: Chinese vaccine manufacturer with WHO-prequalified OPV and other pediatric vaccines supplied through UNICEF; competes for limited polio and routine pediatric vaccine tenders globally.
• Serum Institute of India (SII): BBio's parent company is the world's largest vaccine manufacturer by volume, producing polio, DTP, measles and other pediatric vaccines for UNICEF and Gavi; competes with BBio for the same tenders but also drives European product introductions through BBio.
• GSK Vaccines: GlaxoSmithKline operates one of the world's largest vaccine businesses, including polio-containing combination vaccines and EU MAH positions, making it a direct competitor for EU public tenders and Gavi/UNICEF supply contracts.

Broad incumbents

• Catalent: Global CDMO offering viral vector, mammalian cell culture and fill-finish services; competes with BBio for biotech CDMO contracts in vaccines and gene therapy.
• Samsung Biologics: Large-scale biologics CDMO with rapidly expanding mammalian and viral vector capacity; competes with BBio for premium CDMO contracts and partnership opportunities for European biotech customers.
• Lonza Group: One of the largest global CDMOs with mammalian and viral vector capabilities, frequently partnering with biotech and pharma customers on vaccines and biologics that could otherwise be served by BBio's BSL 2/3 platforms.
• Merck & Co. (MSD) Vaccines: Large diversified vaccine manufacturer with established global public-health and pandemic preparedness partnerships; offers broader portfolio but overlaps with BBio on certain pediatric and travel vaccines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bilthoven-biologicals
• Xx.com/BBio_nl
• Facebookfacebook.com/bilthovenbiologicals

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bilthoven Biologicals